Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 435658, 10 pages
http://dx.doi.org/10.1155/2015/435658
Research Article

Prolactin and Dehydroepiandrosterone Levels in Women with Systemic Lupus Erythematosus: The Role of the Extrapituitary Prolactin Promoter Polymorphism at −1149G/T

1Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA
2National Human Genome Research Institute, Rockville, MD 20892, USA
3FDA-National Center for Toxicological Research, Jefferson, AR 72079, USA

Received 2 January 2015; Revised 27 April 2015; Accepted 28 April 2015

Academic Editor: Lingyun Sun

Copyright © 2015 Edward L. Treadwell et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Lupus Foundation of America, Statistics about Lupus, Lupus Foundation of America, Washington, DC, USA, 2007, http://www.lupus.org/about/statistics-on-lupus.
  2. J. S. Cameron, “Lupus nephritis,” Journal of the American Society of Nephrology, vol. 10, no. 2, pp. 413–424, 1999. View at Google Scholar · View at Scopus
  3. C. C. Mok and C. S. Lau, “Pathogenesis of systemic lupus erythematosus,” Journal of Clinical Pathology, vol. 56, no. 7, pp. 481–490, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. S. K. Datta, L. Zhang, and L. Xu, “T-helper cell intrinsic defects in lupus that break peripheral tolerance to nuclear autoantigens,” Journal of Molecular Medicine, vol. 83, no. 4, pp. 267–278, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. J. S. Smolen, “Therapy of systemic lupus erythematosus: a look into the future,” Arthritis Research & Therapy, vol. 4, supplement 3, pp. S25–S30, 2002. View at Publisher · View at Google Scholar
  6. R. G. Lahita, “Gender and age in lupus,” in Systemic Lupus Erythematosus, R. G. Lahita, Ed., Academic Press, San Diego, Calif, USA, 2004. View at Google Scholar
  7. T. Patavino and D. M. Brady, “Natural medicine and nutritional therapy as an alternative treatment in systemic lupus erythematosus,” Alternative Medicine Review, vol. 6, no. 5, pp. 460–471, 2001. View at Google Scholar · View at Scopus
  8. S. L. E. Lupus Foundation, Facts about Gender and Racial Disparities in Lupus: Lupus Targets Women and Minorities, 2007, http://www.lupusny.org/who.php.
  9. National Institutes of Health and National Institute of Arthritis and Muscoloskeletal and Skin Diseases, Genetic Differences Found in African American, European American Lupus Families, National Institutes of Health, 2002, http://www.niams.nih.gov/ne/highlights/spotlight/2002/lupusgene.htm.
  10. S. P. Crampton, P. A. Morawski, and S. Bolland, “Linking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosus,” Disease Models & Mechanisms, vol. 7, no. 9, pp. 1033–1046, 2014. View at Publisher · View at Google Scholar
  11. M. Fojtíková, P. Čejková, R. Bečvář, J. Vencovský, J. Tomasová Studýnková, and M. Černá, “Polymorphism of the extrapituitary prolactin promoter and systemic sclerosis,” Rheumatology International, vol. 30, no. 12, pp. 1691–1693, 2010. View at Publisher · View at Google Scholar
  12. O. Vera-Lastra, L. J. Jara, and L. R. Espinoza, “Prolactin and autoimmunity,” Autoimmunity Reviews, vol. 1, no. 6, pp. 360–364, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Buskila, M. Lorber, L. Neumann, D. Flusser, and Y. Shoenfeld, “No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus,” Journal of Rheumatology, vol. 23, no. 4, pp. 629–632, 1996. View at Google Scholar · View at Scopus
  14. E. Peeva, D. Michael, J. Cleary, J. Rice, X. Chen, and B. Diamond, “Prolactin modulates the naive B cell repertoire,” Journal of Clinical Investigation, vol. 111, no. 2, pp. 275–283, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Gellersen, R. Kempf, R. Telgmann, and G. E. DiMattia, “Nonpituitary human prolactin gene transcription is independent of Pit-1 and differentially controlled in lymphocytes and in endometrial stroma,” Molecular Endocrinology, vol. 8, no. 3, pp. 356–373, 1994. View at Publisher · View at Google Scholar · View at Scopus
  16. J. S. Dillon, “Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders,” Current Drug Targets: Inflammation and Allergy, vol. 4, no. 3, pp. 377–385, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. C. C. G. Chen and C. R. Parker Jr., “Adrenal androgens and the immune system,” Seminars in Reproductive Medicine, vol. 22, no. 4, pp. 369–377, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Charlton, P. Angulo, N. Chalasani et al., “Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease,” Hepatology, vol. 47, no. 2, pp. 484–492, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. K. L. Wiley, E. Treadwell, K. Manigaba, B. Word, and B. D. Lyn-Cook, “Ethnic differences in DNA methyltransferases expression in patients with systemic lupus erythematosus,” Journal of Clinical Immunology, vol. 33, no. 2, pp. 342–348, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Bole-Feysot, V. Goffin, M. Edery, N. Binart, and P. A. Kelly, “Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice,” Endocrine Reviews, vol. 19, no. 3, pp. 225–268, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. V. Goffin, N. Binart, P. Touraine, and P. A. Kelly, “Prolactin: the new biology of an old hormone,” Annual Review of Physiology, vol. 64, pp. 47–67, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Fojtíková, M. Černá, P. Čejková, Š. Růžičková, and C. Dostál, “Extrapituitary prolactin promoter polymorphism in Czech patients with systemic lupus erythematosus and rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 66, no. 5, pp. 706–707, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Stevens, D. Ray, A. Alansari et al., “Characterization of a prolactin gene polymorphism and its associations with systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 44, no. 10, pp. 2358–2366, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. A. H. Sawalha and S. Kovats, “Dehydroepiandrosterone in systemic lupus erythematosus,” Current Rheumatology Reports, vol. 10, no. 4, pp. 286–291, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. S. J. Mills, J. J. Ashworth, S. C. Gilliver, M. J. Hardman, and G. S. Ashcroft, “The sex steroid precursor DHEA accelerates cutaneous wound healing via the estrogen receptors,” Journal of Investigative Dermatology, vol. 125, no. 5, pp. 1053–1062, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. R. H. Straub, L. Konecna, S. Hrach et al., “Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence,” The Journal of Clinical Endocrinology & Metabolism, vol. 83, no. 6, pp. 2012–2017, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. W. Marder, E. C. Somers, M. J. Kaplan, M. R. Anderson, E. E. Lewis, and W. J. McCune, “Effects of Prasterone (dehydroepiandrosterone) on markers of cardiovascular risk and bone turnover in premenopausal women with systemic lupus erythematosus: a pilot study,” Lupus, vol. 19, no. 10, pp. 1229–1236, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. R. F. van Vollenhoven, E. G. Engleman, and J. L. Mcguire, “An open study of dehydroepiandrosterone in systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 37, no. 9, pp. 1305–1310, 1994. View at Publisher · View at Google Scholar · View at Scopus
  29. R. F. van Vollenhoven, L. M. Morabito, E. G. Engleman, and J. L. McGuire, “Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months,” Journal of Rheumatology, vol. 25, no. 2, pp. 285–289, 1998. View at Google Scholar · View at Scopus
  30. E. M. Simmons, J. Himmelfarb, M. T. Sezer et al., “Plasma cytokine levels predict mortality in patients with acute renal failure,” Kidney International, vol. 65, no. 4, pp. 1357–1365, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Nechemia-Arbely, D. Barkan, G. Pizov et al., “IL-6/IL-6R axis plays a critical role in acute kidney injury,” Journal of the American Society of Nephrology, vol. 19, no. 6, pp. 1106–1115, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Rose-John, G. H. Waetzig, J. Cheller, J. Grötzinger, and D. Seegert, “The IL-6/sIL-6R complex as a novel target for therapeutic approaches,” Expert Opinion on Therapeutic Targets, vol. 11, no. 5, pp. 613–624, 2007. View at Publisher · View at Google Scholar · View at Scopus